Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study
A. M. D'Armini, H. A. Ghofrani, N. H. Kim, E. Mayer, G. Simonneau, M. R. Wilkins, T. Pulido, A. Fritsch, N. Davie, M. M. Hoeper (Pavia, Italy; Giessen, Bad Nauheim, Wuppertal, Hannover, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom; Mexico City, Mexico)
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. M. D'Armini, H. A. Ghofrani, N. H. Kim, E. Mayer, G. Simonneau, M. R. Wilkins, T. Pulido, A. Fritsch, N. Davie, M. M. Hoeper (Pavia, Italy; Giessen, Bad Nauheim, Wuppertal, Hannover, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom; Mexico City, Mexico). Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study. Eur Respir J 2013; 42: Suppl. 57, 2598
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: